Literature DB >> 28683962

Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer.

Brian S Finkelman1, Mary Putt1, Teresa Wang2, Le Wang1, Hari Narayan3, Susan Domchek4, Angela DeMichele5, Kevin Fox4, Jennifer Matro4, Payal Shah4, Amy Clark4, Angela Bradbury4, Vivek Narayan4, Joseph R Carver6, W H Wilson Tang7, Bonnie Ky8.   

Abstract

BACKGROUND: Oxidative/nitrosative stress and endothelial dysfunction are hypothesized to be central to cancer therapeutics-related cardiac dysfunction (CTRCD). However, the relationship between circulating arginine-nitric oxide (NO) metabolites and CTRCD remains unstudied.
OBJECTIVES: This study sought to examine the relationship between arginine-NO metabolites and CTRCD in a prospective cohort of 170 breast cancer patients treated with doxorubicin with or without trastuzumab.
METHODS: Plasma levels of arginine, citrulline, ornithine, asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and N-monomethylarginine (MMA) were quantified at baseline, 1 month, and 2 months after doxorubicin initiation. Determinants of baseline biomarker levels were identified using multivariable linear regression, and Cox regression defined the association between baseline levels and 1- or 2-month biomarker changes and CTRCD rate in 139 participants with quantitated echocardiograms at all time points.
RESULTS: Age, hypertension, body mass index, and African-American race were independently associated with ≥1 of baseline citrulline, ADMA, SDMA, and MMA levels. Decreases in arginine and citrulline and increases in ADMA were observed at 1 and 2 months (all p < 0.05). Overall, 32 participants experienced CTRCD over a maximum follow-up of 5.4 years. Hazard ratios for ADMA and MMA at 2 months were 3.33 (95% confidence interval [CI]: 1.12 to 9.96) and 2.70 (95% CI: 1.35 to 5.41), respectively, and 0.78 (95% CI: 0.64 to 0.97) for arginine at 1 month.
CONCLUSIONS: In breast cancer patients undergoing doxorubicin therapy, early alterations in arginine-NO metabolite levels occurred, and early biomarker changes were associated with a greater CTRCD rate. Our findings highlight the potential mechanistic and translational relevance of this pathway to CTRCD.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  arginine metabolism; cardio-oncology; cardiotoxicity; doxorubicin; nitrosative stress; trastuzumab

Mesh:

Substances:

Year:  2017        PMID: 28683962      PMCID: PMC5665653          DOI: 10.1016/j.jacc.2017.05.019

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  44 in total

1.  Robustness of ordinary least squares in randomized clinical trials.

Authors:  David R Judkins; Kristin E Porter
Journal:  Stat Med       Date:  2015-12-23       Impact factor: 2.373

2.  Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.

Authors:  Edith Pituskin; John R Mackey; Sheri Koshman; Davinder Jassal; Marshall Pitz; Mark J Haykowsky; Joseph J Pagano; Kelvin Chow; Richard B Thompson; Larissa J Vos; Sunita Ghosh; Gavin Y Oudit; Justin A Ezekowitz; D Ian Paterson
Journal:  J Clin Oncol       Date:  2016-11-28       Impact factor: 44.544

3.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

4.  Endogenous methylarginines modulate superoxide as well as nitric oxide generation from neuronal nitric-oxide synthase: differences in the effects of monomethyl- and dimethylarginines in the presence and absence of tetrahydrobiopterin.

Authors:  Arturo J Cardounel; Yong Xia; Jay L Zweier
Journal:  J Biol Chem       Date:  2004-12-01       Impact factor: 5.157

5.  Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis.

Authors:  Charalambos Antoniades; Cheerag Shirodaria; Paul Leeson; Alexios Antonopoulos; Nicholas Warrick; Tim Van-Assche; Colin Cunnington; Dimitris Tousoulis; Ravi Pillai; Chandi Ratnatunga; Christodoulos Stefanadis; Keith M Channon
Journal:  Eur Heart J       Date:  2009-03-18       Impact factor: 29.983

6.  Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.

Authors:  Jersey Chen; Jessica B Long; Arti Hurria; Cynthia Owusu; Richard M Steingart; Cary P Gross
Journal:  J Am Coll Cardiol       Date:  2012-11-14       Impact factor: 24.094

7.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity.

Authors:  Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh
Journal:  Nat Med       Date:  2012-10-28       Impact factor: 53.440

8.  Asymmetric dimethylarginine, race, and mortality in hemodialysis patients.

Authors:  David A Drew; Hocine Tighiouart; Tammy Scott; Amy Kantor; Li Fan; Carlo Artusi; Mario Plebani; Daniel E Weiner; Mark J Sarnak
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-26       Impact factor: 8.237

Review 9.  Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.

Authors:  Virginia Shalkey Hahn; Daniel J Lenihan; Bonnie Ky
Journal:  J Am Heart Assoc       Date:  2014-04-22       Impact factor: 5.501

10.  Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.

Authors:  Erin J Aiello Bowles; Robert Wellman; Heather Spencer Feigelson; Adedayo A Onitilo; Andrew N Freedman; Thomas Delate; Larry A Allen; Larissa Nekhlyudov; Katrina A B Goddard; Robert L Davis; Laurel A Habel; Marianne Ulcickas Yood; Catherine McCarty; David J Magid; Edward H Wagner
Journal:  J Natl Cancer Inst       Date:  2012-09-05       Impact factor: 13.506

View more
  29 in total

1.  Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.

Authors:  Jenica N Upshaw; Robin Ruthazer; Kathy D Miller; Susan K Parsons; John K Erban; Anne M O'Neill; Biniyam Demissei; George Sledge; Lynne Wagner; Bonnie Ky; David M Kent
Journal:  Clin Breast Cancer       Date:  2019-05-02       Impact factor: 3.225

2.  Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy.

Authors:  Biniyam G Demissei; Brian S Finkelman; Rebecca A Hubbard; Liyong Zhang; Amanda M Smith; Karyn Sheline; Caitlin McDonald; Hari K Narayan; Vivek Narayan; Adam J Waxman; Susan M Domchek; Angela DeMichele; Payal Shah; Amy S Clark; Angela R Bradbury; Joseph R Carver; Jenica Upshaw; Saro H Armenian; Peter Liu; Bonnie Ky
Journal:  Cancer       Date:  2019-05-01       Impact factor: 6.860

Review 3.  Biomarker Discovery in Cardio-Oncology.

Authors:  Anita Vohra; Aarti Asnani
Journal:  Curr Cardiol Rep       Date:  2018-05-25       Impact factor: 2.931

Review 4.  Precision Cardio-Oncology.

Authors:  Alexandra D Dreyfuss; Paco E Bravo; Constantinos Koumenis; Bonnie Ky
Journal:  J Nucl Med       Date:  2019-01-17       Impact factor: 10.057

Review 5.  Cardio-oncology: protecting the heart from curative breast cancer treatment.

Authors:  Jenica N Upshaw
Journal:  Gland Surg       Date:  2018-08

Review 6.  Cardiovascular toxicity of breast cancer treatment: an update.

Authors:  Christos Papageorgiou; Angeliki Andrikopoulou; Meletios-Athanasios Dimopoulos; Flora Zagouri
Journal:  Cancer Chemother Pharmacol       Date:  2021-04-17       Impact factor: 3.333

Review 7.  Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers.

Authors:  Dongqing Chen; Conagh Kelly; Tatt Jhong Haw; Janine M Lombard; Ina I C Nordman; Amanda J Croft; Doan T M Ngo; Aaron L Sverdlov
Journal:  Curr Heart Fail Rep       Date:  2021-11-03

Review 8.  Hypertension in Cancer Survivors: A Review of the Literature and Suggested Approach to Diagnosis and Treatment.

Authors:  David Chuquin; Antonio Abbate; Wendy Bottinor
Journal:  J Cardiovasc Pharmacol       Date:  2022-10-01       Impact factor: 3.271

Review 9.  Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity.

Authors:  Lars Michel; Tienush Rassaf; Matthias Totzeck
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 10.  Research progress of biomarkers in early detection of chemotherapy-induced cardiotoxicity.

Authors:  Wanli Gai; Jian An; Zhixin Wang; Xuebin Han; Jianhui Geng; Yunliang Liang; Yanqing Guo
Journal:  Heart Fail Rev       Date:  2021-09       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.